文献リスト

1) 日本糖尿病学会. 糖尿病診断基準が11年ぶりに改訂. 日本医事新報. 2010; 4493: 4-6

2) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-53

3) Hyvärinen M, Tuomilehto J, Mähönen M, et al; DECODE Study Group. Hyperglycemia and incidence of ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose criteria. Stroke. 2009; 40: 1633-7

4) Burchfiel CM, Curb JD, Rodriguez BL, et al. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke. 1994; 25: 951-7

5) Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979; 241: 2035-8

6) Barrett-Connor E, Khaw KT. Diabetes mellitus: an independent risk factor for stroke？ Am J Epidemiol. 1988; 128: 116-23

7) Tuomilehto J, Rastenyte D, Jousilahti P, et al. Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population. Stroke. 1996; 27: 210-5

8) Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care. 1998; 21: 539-45

9) Hart CL, Hole DJ, Smith GD. Comparison of risk factors for stroke incidence and stroke mortality in 20 years of follow-up in men and women in the Renfrew/Paisley Study in Scotland. Stroke. 2000; 31: 1893-6

10) DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001; 161: 397-405

11) Folsom AR, Rasmussen ML, Chambless LE, et al. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. Diabetes Care. 1999; 22: 1077-83

12) Oizumi T, Daimon M, Jimbu Y, et al. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-the Funagata study. Metabolism. 2008; 57: 333-8

13) Zhang Y, Galloway JM, Welty TK, et al. Incidence and risk factors for stroke in American Indians: the Strong Heart Study. Circulation. 2008; 118: 1577-84

14) Boden-Albala B, Cammack S, Chong J, et al. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care. 2008; 31: 1132-7

15) Doi Y, Ninomiya T, Hata J, et al. Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study. Stroke. 2010; 41: 203-9

16) 土井康文, 清原 裕. 脳血管障害と糖尿病—疫学研究から. 脳と循環. 2010; 15: 19-23

17) Matsumoto K, Miyake S, Yano M, et al. Insulin resistance and classic risk factors in type 2 diabetic patients with different subtypes of ischemic stroke. Diabetes Care. 1999; 22: 1191-5

18) Urabe T, Watada H, Okuma Y, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke. 2009; 40: 1289-95

19) Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999; 22: 920-4

20) Is fasting glucose sufficient to define diabetes？ Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Diabetologia. 1999; 42: 647-54

21) Nakagami T; DECODA Study Group. Hyper-glycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004; 47: 385-94

22) Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344: 1343-50

23) Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403

24) Chiasson JL, Josse RG, Gomis R, et al: STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359: 2072-7

25) Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004; 35: 1073-8

26) Taylor A, Shaw LJ, Fayad Z, et al. Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis. 2005; 180: 1-10

27) Kawamori R, Tajima N, Iwamoto Y, et al; Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009; 373: 1607-14

28) Wilcox R, Bousser MG, Betteridge DJ, et al; PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007; 38: 865-73

29) Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006; 296: 2572-81

30) DeFronzo RA, Banerji MA, Bray GA, et al; ACT NOW Study Group. Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia. 2010; 53: 435-45

31) NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010; 362: 1463-76

32) Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54: 1615-25

33) Özcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. 2004; 306: 457-61

34) 山岸昌一. 糖尿病大血管症の発症・進展の分子メカニズム－糖化反応. 日本臨牀. 2010; 68: 809-13

35) Yamagishi S, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev. 2005; 1: 93-106

36) Reddy MA, Villeneuve LM, Wang M, et al. Role of the lysine-specific demethylase 1 in the proinflammatory phenotype of vascular smooth muscle cells of diabetic mice. Circ Res. 2008; 103: 615-23

37) Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-89

38) The Diabetes Control and Complication Trial (DCCT) research group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995; 75: 894-903

39) Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353: 2643-53

40) Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59

41) Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-72

42) Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-39

43) UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-65

44) Charbonnel B, Dormandy J, Erdmann E, et al; PROactive Study Group. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardio-vascular events in diabetes？ Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004; 27: 1647-53

45) Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366: 1279-89

46) Wilcox R, Kupfer S, Erdmann E; PROactive Study investigators. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Am Heart J. 2008; 155: 712-7

47) Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009; 373: 1765-72

48) Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b4909. doi: 10. 1136/bmj. b4909

49) Miller ME, Bonds DE, Gerstein HC, et al; ACCORD Investigators. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010; 340: b5444. doi: 10. 1136/bmj. b5444

50) Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295: 1681-7

51) Khaw KT, Wareham N, Bingham S, et al. Association of hemoglobin A1c with cardio-vascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004; 141: 413-20

52) Kawasumi M, Tanaka Y, Uchino H, et al. Strict glycemic control ameliorates the increase of carotid IMT in patients with type 2 diabetes. Endocr J. 2006; 53: 45-50

53) Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004; 364(9435): 685-96

54) Collins R, Armitage J, Parish S, et al; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361: 2005-16

55) Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366: 1849-61

56) Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-91

57) Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and prognosis of stroke in non-diabetic patients: a systematic overview. Stroke. 2001; 32: 2426-32

58) Cronberg T, Rytter A, Asztély F, et al. Glucose but not lactate in combination with acidosis aggravates ischemic neuronal death in vitro. Stroke. 2004; 35: 753-7

59) 髙橋愼一, 鈴木則宏. 脳虚血病態と糖代謝障害. Diabetes Frontier. 2009; 20: 572-6

60) Quinn TJ, Lees KR. Hyperglycaemia in acute stroke--to treat or not to treat. Cerebrovasc Dis. 2009; 27(Suppl 1): 148-55

61) Gray CS, Hildreth AJ, Sandercock PA, et al; GIST Trialists Collaboration. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol. 2007; 6: 397-406

62) Bruno A, Kent TA, Coull BM, et al. Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke. 2008; 39: 384-9

63) Johnston KC, Hall CE, Kissela BM, et al; GRASP Investigators. Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial. Stroke. 2009; 40: 3804-9

64) McCormick M, Hadley D, McLean JR, et al. Randomized, controlled trial of insulin for acute poststroke hyperglycemia. Ann Neurol. 2010; 67: 570-8

65) Kruyt ND, Biessels GJ, Devries JH, et al. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol. 2010; 6: 145-55

66) Alquier T, Leloup C, Lorsignol A, et al. Translocable glucose transporters in the brain. Where are we in 2006？ Diabetes. 2006; 55(Suppl 2): S131-S138

67) Plum L, Belgardt BF, Brüning JC. Central insulin action in energy and glucose homeostasis. J Clin Invest. 2006; 116: 1761-6

68) 髙橋愼一. 脳虚血とNeurovascular unit. 医学のあゆみ. 2009; 231: 339-46

69) 髙橋愼一. NVUにおける脳血管関門の機能. 分子脳血管病. 2010; 9: 275-281

70) Petrica L, Petrica M, Munteanu M, et al. Cerebral microangiopathy in patients with non-insulin-dependent diabetes mellitus. Ann Acad Med Singapore. 2007; 36: 259-66

71) McCall AL. Cerebral glucose metabolism in diabetes mellitus. Eur J Pharmacol. 2004; 490: 147-58

72) McCall AL. Altered glycemia and brain-update and potential relevance to the aging brain. Neurobiol Aging. 2005; 26S: S70-5

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp